Press Release
Why will Trump win the 2020 election?
When people think, God laughs. Trump will definitely win this election. No reason is needed, just believing. In order to avoid being labelled as a god-stick, I will talk about Eastern Zen Buddhism. When Master Bodhidharma taught the Dharma, he said that “no words are directed at people’s hearts”, pointing out that truth cannot be expressed in words, and what is expressed in words is not truth. The Diamond Sutra Buddha Shakyamuni also stated that the Buddha has never taught the real Dharma, and everything I say is not the righteous Dharma. Lao Tzu’s Tao Te Ching preaches, Tao can be very Tao, Tao is simple. Also said the unspeakable truth.
Let’s talk about the amazing experimental results of modern biology and neurology. After rigorous scientific experiments, experimental experts have discovered that the time for humans to act is before the thinking and decisions of the human brain. What does this mean? That is to say, before your brain makes a decision, your nerves command your body to act before your thinking and decision-making, but the time is so short that you can’t even notice it. Therefore, the destiny of human beings is predestined, and our brain’s thinking is only an explanation based on the results that we can understand and believe in our own behavior. In other words, we mistakenly believe that our destiny is the result of our own thinking and choices, not determined by karma and the Creator.
Therefore, I said that Trump will definitely win the 2020 election. It is a script written by God long ago. We just believe that there is no need to worry and worry. Wu Chengen, the author of Journey to the West, has a metaphor at the end of the book, that is, the Buddha recites in Tang Seng and his apprentices are not far away, and the sincerity of seeking the scriptures after hardships is commendable. At the beginning, the Tang Seng was given the Lingshan Supreme Treasure Without Words scripture, but Tang Seng discovered halfway through Later, he returned to the false scriptures, which was supposed to be a mockery of him. Finally, the Buddha lamented the dullness of the sentient beings in Nanchan Tribe, and gave Tang Seng the scriptures with words that he believed were true scriptures. As the saying goes, there must be chaos. As time goes by, the chaos of the age of human nature is degenerate, and this is the root of the chaos.
The above text is just as everyone is worried about Trump. Now, let’s make a joke with everyone and relax. Next, we will use the habit of giving reasons to believe and talk about why Trump will win the 2020 election.
First of all, in the 2020 election, Trump and Biden have both said that they won? So, is the truth important or Trump’s win?
It is more important than Trump’s win. If we think that as long as Trump can win us regardless of the truth, then Trump is just like Biden by all means to win. We are not worthy to support Trump. Therefore, we first believe that the truth is that Trump is the president elected by most Americans, and Biden’s subsequent overtake is the result of cheating.
The fact is also that all the states where Biden later overtook the bizarre number of votes than registered voters. Suddenly, there was no reason to stop counting votes. After a few hours, Biden was in a rocket-like lead; there were no more than 100,000 votes in the midnight ghost. Exceptions are Biden; countless people who have been dead for many years are voting; many voters are shown to be over 120 or even 170 years old; thousands of votes cast by Trump are found to be counted as Biden; democracy Party states violated regulations to prohibit Republican vote-taking inspectors from jointly scrutinizing votes; some states use the voting system produced by Pelosi’s companies, whether or not Trump’s votes are recorded as voting for Biden, and so on. Then according to many Statehouse synchronized elections member of Republican senators are leading Democrat victory over a dozen points, while in the same region Trump has lost Biden to analyze the phenomenon, in addition to the Democratic ballot fraud cheating In addition, the only explanation is that the local voters are schizophrenic. They voted for Republican congressmen, but they magically voted for the Democratic president.
Therefore, there are no waves without wind, and there must be demons in the abnormal. We have reason to believe the truth is that Trump significantly ahead of Biden, and actually 11 Yue 3 statutory election day has been fantastic, and then to begin the Democrats no bottom line in several key states, no scruples, unprincipled vote cheating Falsification has led to the current situation where Biden has overtaken and is almost winning, and this kind of vote falsification is a premeditated, well-prepared and widely organized behavior.
Then the current crisis so acute Biden and White House seems one step, one-sided mainstream media social software to Biden’s case, Trump win it? Yes, Trump will definitely win, he will enter the White House in 2021 , lead the United States, lead the world, and complete his unfinished business, and the four-year Trump term in the second term will be more exciting and more exciting than the first term. People are excited because Trump never disappoints his supporters and always gives more than expected. In the 2020 U.S. election, Trump will win and must win, because if Trump is cheated by the Biden Democratic Party this time, there will never be a future. This is the final battle. If we cannot defend our votes this time, there will be no votes that truly represent our will in the future.
Talk about three reasons Trump must win:
The first administrative judicial system to resolve disputes peacefully is beneficial to Trump
A major feature of democratic countries is that there are disputes that can be resolved peacefully instead of violence by relying on a trustworthy system. The separation of powers in the United States: Judiciary, Congress, and Administration. The number of Supreme Court justices is the absolute advantage of the Republican Party. Trump counts as one point; Congress Trump controls the Senate majority party as 0.5 points; Biden controls the House majority party as 0.5 points; the administration is controlled by Trump’s White House team and counts one point; if necessary If the mainstream media is considered the fourth right, then Biden is one point; the comparison is that Trump 2.5 points to Biden 1.5 points, and Trump is better than Biden in resolving disputes between the two sides of a normal procedure and peaceful gentleman.
The second people have the awareness and ability to defend the elected President Trump with arms
Trump’s Republican Party has always supported the American people’s right to own guns, while the Democrats are the opposite. Because Gong Huo Party Performed constitutional rationale idea is that the American people have the right to armed overthrow of tyranny, so people have the right gun. As the saying goes, there is a lingering fragrance in the hands of roses. Armed people also have the ability to defend their elected president. Most of the supporters of the Republican Party are voters with gun ideas and qualifications. Various militia organizations and firearms associations will hold weapons to deter all conspiracies that dare to use improper means to overthrow the elected president. In the face of such an armed people, any conspirator must be cautious when doing evil. The key is that the only possible participation of the armed forces police force is Trump’s staunch supporter, thanks to the Biden Democratic Party for supporting Antifa and other ultra-left organizations to mess up the United States to fish in troubled waters and long-term suppression of the police system. US military owned by the state is not involved in internal party strife, that decorum situation under conditions, Trump force values can be easily rolled Biden Democrats. To put it straightforwardly, Biden controls the American moneybags (Wall Street and big capitalists) and pens (mainstream media and high-tech companies), but Trump controls the American knives (police and armed people). If the Democratic Party can’t resolve the election disputes peacefully by playing a rogue, the knife is much easier to use than a purse and a pen.
Third, Trump’s Taoists help others to help themselves
One of the most critical factors for Trump to win is that Trump deserves this victory! He is a tough fighter who will never give up. In the face of even more sinister conspiracies and powerful enemies, as long as you don’t give up, someone will fight with you until you succeed. Trump has proven to us that he is a warrior who is more and more courageous until victory. The Biden Democrats are accustomed to conspiracy, but this time the bully found the wrong opponent and kicked it on the steel plate. The U.S. Supreme Court has intervened in the vote fraud case at Trump’s request; the U.S. Senate and the Republican Party have announced that they will stand with Trump under any circumstances; voters in 50 U.S. states have begun to take to the streets to support Trump and protect their President recapture the votes are represented by Democrat Joe Biden; large main American religious teachings explicitly called on all those who believe in God the United States (population accounted for 60% ) strongly supports Trump, is standing on the side of God against the sub-plot to reshape the world of darkness; There are also the jealous relatives of Trump’s first family from his wife to his son, daughter, and son-in-law, who have always given Trump spiritual and deed support that others cannot give.
The most important thing is in God and with Donald Trump, Trump with God and in the upper Di and with Donald Trump in. Many friends think that God’s blessing is just a blessing, but I think this is the fundamental factor that Trump must win, because apart from this, the rest are for people to understand and talk about, and this is the real reason. Friends, we ask ourselves why we support Trump? Is it for the benefit of policy or to make more money for yourself, or is it because you hate Biden? If it is not, it is because we want to see justice done, fairness upheld, truth can be announced, and freedom protected. We believe that Trump represents light and hope, and we support the production and generalization so that our children can live in a beautiful, fair and orderly world in the future, so please believe that our support for Trump is a blessed power. It comes from the original love of all things. So Trump will surely get God’s favor.
Why is Trump sure to win, because God is with Trump, the son of light, and all those who support Trump because of love!
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
AI Labs leverages Google’s Gemini AI to bring market analysis into its Chatbot
Singapore – 19/11/2026 – (SeaPRwire) – AI Labs chatbot, AIV, combines crypto and equity market analysis with trading strategies and risk assessments, as it reports about 700,000 active users, daily trading volumes of US$50-100M a day, and total value locked (TVL) of $80-100M across its platform.
AI Labs is using Google‘s Gemini artificial intelligence technology to power its AIV Chatbot, enabling users to explore cryptocurrency and equity markets through conversational analysis, trading scenarios and investment risk assessments.
The chatbot goes beyond conventional price summaries by incorporating technical indicators, business fundamentals, institutional sentiment and market catalysts. It can also outline potential entry and exit levels, evaluate alternative trading strategies and identify risks that could undermine an investment thesis.

“Our aim is to help users understand not just a market view, but the reasoning and risks behind it,“ said Ryan Chi, founder and chief executive officer of AI Labs. “AIV brings those elements into a conversation, so users can explore different scenarios rather than rely on a standalone buy or sell signal.“
Examples provided by the company demonstrate the chatbot‘s capabilities across multiple assets. A Bitcoin query generates a seven-day trading scenario incorporating technical support levels, ETF flows and downside risks. An Nvidia analysis combines technical indicators with growth prospects, valuation and earnings volatility, while a Solana example explores long-short strategies and liquidation risks.
“The important distinction is between generating a trading idea and explaining the assumptions and risks behind it,“ said Terry Tan, an advisor to AI Labs. “AI-powered tools should support independent judgment by helping users understand both opportunities and potential downside scenarios.“
The company says it is continuing to onboard new users and is committed to making every reasonable effort to sustain the high levels of trading activity at US$50-100M daily as it expands its AI-powered financial services.
Media Contact
Company: AI Labs
Contact: Media Team
Email: ryan@academic-labs.org
Website: https://ai-labs.live/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
China Medical System’s Innovative Oral Drug for Vitiligo, Povorcitinib Enrolls First Patient in China Phase III Clinical Trial
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”, 867.HK/8A8.SG) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited), has enrolled the first patient in the China Phase III clinical trial of its innovative oral JAK1 inhibitor Povorcitinib Phosphate Tablets (“povorcitinib” or the “Product”) for the treatment of vitiligo on 19 November 2026.
The trial is a multi-center, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of povorcitinib in Chinese adult patients with non-segmental vitiligo. Led by Professor Li Chunying of the First Affiliated Hospital of Air Force Medical University, the study is planned to be conducted at approximately 44 clinical research centers across China and is expected to enroll approximately 174 patients with non-segmental vitiligo.
The Product has previously completed a series of clinical trials related to pharmacokinetics and bioequivalence in healthy participants in China, and has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”). This certification has the potential to accelerate its development and review process. The enrollment of the first patient in this China Phase III clinical trial marks a pivotal stage in the Product’s clinical development in China and lays a foundation for further evaluating its efficacy and safety in Chinese patients with vitiligo.
Addressing Unmet Clinical Needs in Vitiligo with Novel and Differentiated Treatment Options
Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Currently, treatment options are limited for vitiligo patients who require systemic therapy, and their clinical treatment needs remain inadequately met.
Overactivity of certain proinflammatory cytokines that signal through the JAK-STAT pathway, is believed to drive inflammation and contribute to the pathogenesis and progression of vitiligo. Incyte has announced that Phase III clinical studies outside China of the oral JAK1 inhibitor Povorcitinib Phosphate Tablets in adults with non-segmental vitiligo have met the primary endpoints[2]. If approved in China, the Product has the potential to provide a new oral treatment option for patients with non-segmental vitiligo and, together with Dermavon’s commercialized innovative drug Lumirix® (ruxolitinib phosphate cream), provide vitiligo patients with comprehensive and diversified treatment options, from precise topical intervention to systemic treatment.
Focusing on major skin diseases such as vitiligo, atopic dermatitis and psoriasis, Dermavon has developed an innovative product portfolio covering different disease stages and clinical needs. The enrollment of the first patient in the Phase III clinical trial of povorcitinib in China represents another important milestone in Dermavon’s advancement of local clinical development for global innovative drugs. Going forward, Dermavon will continue to leverage its strong global R&D partnerships and clinical development capabilities in China to accelerate the translation of innovation into clinical application and bring more professional and differentiated treatment options to patients with skin diseases in China.
More Information About Povorcitinib Phosphate Tablets
Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. In addition to vitiligo, the Product has also demonstrated development potential in other indications. Incyte is conducting Phase III clinical trials of povorcitinib for the treatment of prurigo nodularis (PN) in several countries outside China, and has obtained European Commission approval for hidradenitis suppurativa (HS). Dermavon may also consider initiating clinical development of the Product in China for the treatment of additional skin-related diseases.
A subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to China Medical System Holdings Limited (excluding Dermavon and its subsidiaries).
About CMS
CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value.
CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network.
CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development.
Reference
1、China Insights Consultancy (CIC) report
2、Public information on the Incyte official website:https://investor.incyte.com/news-releases/news-release-details/incyte-reports-first-quarter-2026-financial-results-and-provides
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
ONAR’s Largest Acquisition Closed With Two Days Left in Q3
NYC, New York, November 19th, 2026, FinanceWire
ONAR Holding Corporation (OTCID: ONAR) acquired affiliate marketing firm Advertise Purple on September 29, two days before the books closed on its third quarter. That timing left shareholders with an unusual snapshot. ONAR recorded the obligations it took on to buy a business more than three times its size by revenue, while just two days of that business’s sales counted toward the $1.06 million ONAR reported for the quarter.
Had ONAR owned Advertise Purple throughout the quarter, the two businesses would have generated $4.44 million in revenue, according to unaudited figures in CEO Claude Zdanow’s stockholder letter. Over the first nine months of 2026, combined revenue would have totaled $13.52 million, compared with the $3.13 million ONAR reported. Those figures show the historical scale of the business ONAR bought. They exclude interest on the acquisition debt and assume no cost savings from bringing the companies together.
What Advertise Purple brings to ONAR
The first signs of integration are showing up in how the two businesses find customers. JUICE, an ONAR marketing agency, now handles Advertise Purple’s own marketing and has brought it new business, according to Zdanow. Advertise Purple’s sales team, in turn, sends leads to JUICE each month. Its core leadership team stayed on after the acquisition.
ONAR is also introducing its technology to Advertise Purple’s teams and clients, including Cortex, which helps marketers connect advertising activity with online and offline sales. The fourth quarter will give shareholders their first full reporting period to assess how the businesses perform under common ownership.
Why the Nasdaq application matters
ONAR’s reported nine-month revenue rose 68% year over year, and its operating loss narrowed 60%. The company still posted a $3.61 million net loss and used $590,000 in cash from operations. Interest accounted for nearly three-quarters of the net loss, according to ONAR, and most of that interest was noncash.
At September 30, ONAR had $37.7 million in total liabilities, up from $9.7 million at the start of the year. About $16.4 million represented acquisition payments due over time, including an earnout tied to Advertise Purple’s performance. ONAR ended the quarter with a $15.2 million working capital deficit and said its filings continue to identify substantial doubt about its ability to continue as a going concern.
That puts financial weight behind ONAR’s pursuit of a Nasdaq Capital Market listing. A qualifying national exchange listing would automatically convert $11 million in junior secured notes into preferred stock. Without a listing, those notes remain outstanding and mature in March 2028. ONAR has approved a 1-for-250 reverse stock split as part of its listing preparations. The split has yet to take effect, and Nasdaq approval remains uncertain.
For shareholders, the next operating milestone comes with ONAR’s annual report. It will include the first full quarter of Advertise Purple’s revenue and expenses under ONAR ownership, giving investors a clearer view of what the larger business earns and how much cash it uses.
About ONAR Holding Corporation
ONAR (pronounced “Honor”) is an AI-powered marketing platform. ONAR acquires and operates specialist marketing agencies serving middle-market and growth-stage brands across performance marketing, creative, and commerce, and runs them on shared proprietary technology designed to automate up to 70% of manual agency work. Its technology division, ONAR Labs, develops and houses that technology, including ONAR AI, a marketing intelligence platform deployed across the Company’s agencies; Retina AI, a predictive customer intelligence platform; and Cortex, an offline and online sales attribution platform.
Together, these products are designed to make the Company’s teams more productive and to shift agency work from billable hours toward measurable client results. ONAR continues to expand the platform through disciplined acquisitions, including JUICE, Scale Partner, and Advertise Purple.
Learn more at https://www.onar.com/
Contact
President
Craig Fischer
ValueCorp
cf@valuecorptrading.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
-
Press Release1 week ago
Midwest Ragdolls Explains Why Playful Kitten Biting Is Often Misunderstood
-
Press Release2 days ago
OiLChef Wins Restaurant Solution of the Year Award at 2026 Restaurant & Takeaway Innovation Expo
-
Press Release1 week ago
ARCPE Holding, LLC Highlights the Importance of Understanding Local Real Estate Market Conditions
-
Press Release5 days ago
IntelliVIX Wins Two CES 2027 Innovation Awards, Showcasing Global Competitiveness in Safety AI
-
Press Release7 days ago
Red Banyan CEO Evan Nierman Leads High-Stakes Communications Workshop at NASDDDS Annual Conference
-
Press Release5 days ago
Rifstone Capital LLC Advances Institutional Research Platform with Expanded Global Allocation Framework
-
Press Release1 week ago
Dasher Personalized Running Highlights Personalized Half Marathon Training Plans Focused on Injury Prevention and Sustainable Progress
-
Press Release5 days ago
Eurotrace net Unveils New Blockchain Intelligence Research Initiative
